TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05212766

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Infections with COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: BIOLOGICAL
Intervention: COVID vaccination
Description: Vaccination against COVID 19

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Assessment of oral and periodontal health status
Study: NCT06433596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shock waves therapy
Description: 6 sessions of focal shock waves, 1 per week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PRP
Description: 3 injections of 10 cc of saline solution, weeks 1, 5 and 9

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PRP
Description: 3 injections of 10 cc of saline solution, weeks 1, 5 and 9

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham shock waves therapy
Description: 6 sessions of sham shock waves, 1 per week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham shock waves therapy
Description: 6 sessions of sham shock waves, 1 per week
Study: NCT04446390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Himalaya complete care toothpaste
Description: Herbal toothpaste as a part of a caries preventive regimen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colgate cavity protection
Description: fluoride toothpaste as a part of a caries preventive regimen
Study: NCT05731050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed.
Study: NCT04757428

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocrown
Description: Endocrown

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocrown
Description: Endocrown
Study: NCT05294081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: 10 sessions based on an individualized pain hierarchy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 10 sessions with graded activity, relaxations techniques and cognitive interventions
Study: NCT05427578

Intervention type: OTHER
Intervention: fNIRS measurement
Description: measurement using functional near-infrared spectroscopy

Intervention type: OTHER
Intervention: fNIRS measurement
Description: measurement using functional near-infrared spectroscopy

Intervention type: OTHER
Intervention: fNIRS measurement
Description: measurement using functional near-infrared spectroscopy
Study: NCT04415424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Description: A four-component meningococcal B vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
Study: NCT06055257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified PENTOCLO (mPENTOCLO)
Description: 4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham mPENTOCLO
Description: 4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo).
Study: NCT06246773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Parenting Program
Description: During the first week, women will receive one session of Recovering from Intimate partner violence through Strengths and Empowerment (RISE) and from week 2 they will receive RISE and PALS simultaneously. Participants will receive four to six components of RISE - education on health effects of violence, improving coping and self-care, enhancing social support, and addressing sexual violence, increase safety planning, and assist in making difficult decisions. During each of the PALS sessions, parents will receive instruction on four responsive parenting constructs: contingent responsiveness, warm sensitivity (responses include high levels of affection and understanding of child states), maintaining vs. redirecting attention to objects and topics of conversation, and verbal scaffolding .In addition to direct instruction, parents will video-record themselves interacting with their child and engage in self-reflection of their own parenting behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive services available to them at the shelter or housing facility
Study: NCT04959123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacokinetic analysis
Description: Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacokinetic analysis
Description: Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
Study: NCT06130332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 with chemotherapy
Description: Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor

Intervention type: PROCEDURE
Group type: OTHER
Intervention: upright surgery
Description: Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection
Study: NCT05995535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX/PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LFX/PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFX/PLA-PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LFX/PLA-PGB
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg
Study: NCT05543590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: 5 sessions of plasma exchanges

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood collection to assess biological markers at baseline, M3 and M12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection to assess biological markers at baseline, M3 and M12

Intervention type: OTHER
Group type: OTHER
Intervention: Stool samples
Description: Stool samples will be collected from participants at baseline,M3 and M12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool samples
Description: Stool samples will be collected from participants at baseline,M3 and M12

Intervention type: OTHER
Group type: OTHER
Intervention: PET scan
Description: PET scan at baseline and M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET scan
Description: PET scan at baseline and M6

Intervention type: OTHER
Group type: OTHER
Intervention: Cycle ergometer stress test
Description: Cycle ergometer stress test at M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer stress test
Description: Cycle ergometer stress test at M6

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires at baseline
Description: Questionnaires at baseline, M3 and M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires at baseline
Description: Questionnaires at baseline, M3 and M6

Intervention type: OTHER
Group type: OTHER
Intervention: Medical consultations
Description: Medical consultations
Study: NCT05173129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Posture Analysis
Description: Posture analysis and assessment of mechanical properties of posture muscles
Study: NCT05165498

Intervention type: PROCEDURE
Intervention: Real-time ultrasound guidance for thoracic epidural catheter placement.
Description: With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
Study: NCT05173129

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Posture Analysis
Description: Posture analysis and assessment of mechanical properties of posture muscles
Study: NCT04666311

Intervention type: DIAGNOSTIC_TEST
Intervention: Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB
Description: CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection
Description: CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)
Study: NCT06485999

Intervention type: PROCEDURE
Intervention: Biologically Oriented Preparation Technique
Description: It is a preparation technique without a finish line, also known as the biologically oriented preparation technique (BOPT). In this protocol, the crown's anatomic emergence profile at the cementoenamel junction (CEJ) is eliminated with diamond rotary instruments to create a new prosthetic junction, adapted to the gingival margin. The aim of this protocol is to create a new anatomic crown with a prosthetic emergence profile that simulates the shape of the natural tooth.
Study: NCT05038657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
Study: NCT05746897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM1F Injection
Description: This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period.
Study: NCT06221657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy
Description: 1 tablet once a day, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Virreal
Description: 1 tablet once a day, oral administration
Study: NCT05428878

Intervention type: DIAGNOSTIC_TEST
Intervention: ANS Watch
Description: 1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type

Intervention type: DIAGNOSTIC_TEST
Intervention: ANS Watch
Description: 1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type
Study: NCT05973370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 500 mg
Description: All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
Study: NCT05904626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELGN-2112
Description: To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
Study: NCT05655117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based eye screening
Description: The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
Study: NCT06071312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single FMT
Description: This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sequential FMT
Description: This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
Study: NCT04901572

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: QISI device
Description: QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
Study: NCT05689619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Study: NCT05900440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound with Artificial Inteligence Engabled
Description: Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound without Artificial Intelligence Enabled
Description: Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
Study: NCT05981976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Specified dose on specified days
Study: NCT05501626

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Theta Burst Stimulation (TBS)
Description: Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation (TBS)
Description: Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
Study: NCT05769231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia in Chatbot
Description: Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.